Organogenesis Q1 revenue $36.3M (-58% YoY); net loss $53.2M; FY guidance lowered

Organogenesis Holdings Inc.

2026-Q1 EPS reported -$0.44 revenue$37,228,000

Net revenue $36.3M, down 58% YoY from $86.7M; Advanced Wound Care down 63% to $29.5M.
Net loss $53.2M ($0.44/sh) vs $18.8M loss ($0.17/sh) in Q1 2025; adjusted net loss $43.7M.
Adjusted EBITDA loss $48.2M vs $12.5M loss; gross margin collapsed to 29% from 73%.
FY2026 revenue guidance $270M-$310M, decline of 45%-52% from $564.2M in 2025.
Cash $92.1M, no debt; expects sequential improvement in Q2 and strong H2 growth.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Organogenesis Holdings Inc. reported first quarter ended March 31, 2026 results: revenue $36.3 million, net income Net loss of $53.2 million, EPS $(0.44) per share. Guidance lowered.

Period: first quarter ended March 31, 2026
Revenue: $36.3 million
Net income: Net loss of $53.2 million
EPS: $(0.44) per share
Guidance: lowered
Result: reported results

Exact text from the filing

Net revenue of $36.3 million for the first quarter of 2026

View on SEC.gov

Browse all earnings releases →

Organogenesis Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001661181-26-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.